NCT00780052View on ClinicalTrials.gov

Infusional C-myb ASODN in Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Hematologic Malignancies
Interventions
DRUG

c-myb AS ODN

Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.

Trial Locations (1)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00780052 - Infusional C-myb ASODN in Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter